Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 August 2005, Vol. 106, No. 3, pp. 1063-1066.
Prepublished online as a Blood First Edition Paper on April 19, 2005; DOI 10.1182/blood-2004-08-3225.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2004-08-3225v1
106/3/1063    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sujobert, P.
Right arrow Articles by Bouscary, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sujobert, P.
Right arrow Articles by Bouscary, D.
Related Collections
Right arrow Neoplasia
Right arrow Signal Transduction
Right arrow Brief Reports
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA
Brief report

Essential role for the p110{delta} isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

Pierre Sujobert, Valerie Bardet, Pascale Cornillet-Lefebvre, Joel S. Hayflick, Nolwen Prie, Frederic Verdier, Bart Vanhaesebroeck, Odile Muller, Florence Pesce, Norbert Ifrah, Mathilde Hunault-Berger, Christian Berthou, Bruno Villemagne, Eric Jourdan, Bruno Audhuy, Eric Solary, Brigitte Witz, Jean Luc Harousseau, Chantal Himberlin, Thierry Lamy, Bruno Lioure, Jean Yves Cahn, Francois Dreyfus, Patrick Mayeux, Catherine Lacombe, and Didier Bouscary

From the Département d'Hématologie, INSERM U567, CNRS UMR 8104, Université Paris Descartes 5, Institut Cochin, and Service d'Hématologie and the Département de Statistique, Hôpital Cochin, AP-HP, Paris, France; Laboratoire d'Hématologie, Hôpital de Reims, Reims, France; ICOS Corporation, Bothell, Washington; Ludwig Institute for Cancer Research and the Department of Biochemistry and Molecular Biology, University College London, London, United Kingdom; and Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS), Tours, France.

The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway has been shown to be frequently activated in blast cells from patients with acute myeloid leukemia (AML) and to contribute to survival and proliferation of these cells. Of the 8 distinct mammalian isoforms of PI3K, it is the class I PI3Ks (p110{alpha}, p110{beta}, p110{gamma}, and p110{delta}) that are responsible for Akt activation. It is not known which PI3K isoform is critical in AML. Here we show that the p110{delta} isoform of PI3K is consistently expressed at a high level in blast cells from AML, in contrast to the other class I isoforms, the expression of which was very variable among patients. IC87114, a p110{delta}-selective inhibitor, suppressed both constitutive and Flt-3–stimulated Akt activation in blasts to the same extent as Ly294002, an inhibitor of all PI3K isoforms. Moreover, IC87114 inhibited AML cell proliferation without affecting the proliferation of normal hematopoietic progenitor cells. These observations identify p110{delta} as a potential therapeutic target in AML.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
haematolHome page
C. R. Geest, F. J. Zwartkruis, E. Vellenga, P. J. Coffer, and M. Buitenhuis
Mammalian target of rapamycin activity is required for expansion of CD34+ hematopoietic progenitor cells
Haematologica, July 1, 2009; 94(7): 901 - 910.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Saudemont, F. Garcon, H. Yadi, M. Roche-Molina, N. Kim, A. Segonds-Pichon, A. Martin-Fontecha, K. Okkenhaug, and F. Colucci
p110{gamma} and p110{delta} isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease
PNAS, April 7, 2009; 106(14): 5795 - 5800.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Billottet, L. Banerjee, B. Vanhaesebroeck, and A. Khwaja
Inhibition of Class I Phosphoinositide 3-Kinase Activity Impairs Proliferation and Triggers Apoptosis in Acute Promyelocytic Leukemia without Affecting Atra-Induced Differentiation
Cancer Res., February 1, 2009; 69(3): 1027 - 1036.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
N. T. Ihle and G. Powis
Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy
Mol. Cancer Ther., January 1, 2009; 8(1): 1 - 9.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Zebedin, O. Simma, C. Schuster, E. M. Putz, S. Fajmann, W. Warsch, E. Eckelhart, D. Stoiber, E. Weisz, J. A. Schmid, et al.
Leukemic challenge unmasks a requirement for PI3K{delta} in NK cell-mediated tumor surveillance
Blood, December 1, 2008; 112(12): 4655 - 4664.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Boller, A. Schramm, K. T. Doepfner, T. Shalaby, A. O. von Bueren, A. Eggert, M. A. Grotzer, and A. Arcaro
Targeting the Phosphoinositide 3-Kinase Isoform p110{delta} Impairs Growth and Survival in Neuroblastoma Cells
Clin. Cancer Res., February 15, 2008; 14(4): 1172 - 1181.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Dos Santos, C. Demur, V. Bardet, N. Prade-Houdellier, B. Payrastre, and C. Recher
A critical role for Lyn in acute myeloid leukemia
Blood, February 15, 2008; 111(4): 2269 - 2279.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Tamburini, N. Chapuis, V. Bardet, S. Park, P. Sujobert, L. Willems, N. Ifrah, F. Dreyfus, P. Mayeux, C. Lacombe, et al.
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
Blood, January 1, 2008; 111(1): 379 - 382.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Buitenhuis, L. P. Verhagen, H. W. M. van Deutekom, A. Castor, S. Verploegen, L. Koenderman, S.-E. W. Jacobsen, and P. J. Coffer
Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis
Blood, January 1, 2008; 111(1): 112 - 121.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. M. Schoenwaelder, A. Ono, S. Sturgeon, S. M. Chan, P. Mangin, M. J. Maxwell, S. Turnbull, M. Mulchandani, K. Anderson, G. Kauffenstein, et al.
Identification of a Unique Co-operative Phosphoinositide 3-Kinase Signaling Mechanism Regulating Integrin {alpha}IIbbeta3 Adhesive Function in Platelets
J. Biol. Chem., September 28, 2007; 282(39): 28648 - 28658.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Tamburini, C. Elie, V. Bardet, N. Chapuis, S. Park, P. Broet, P. Cornillet-Lefebvre, B. Lioure, V. Ugo, O. Blanchet, et al.
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients
Blood, August 1, 2007; 110(3): 1025 - 1028.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Y. Follo, S. Mongiorgi, C. Bosi, A. Cappellini, C. Finelli, F. Chiarini, V. Papa, M. Libra, G. Martinelli, L. Cocco, et al.
The Akt/Mammalian Target of Rapamycin Signal Transduction Pathway Is Activated in High-Risk Myelodysplastic Syndromes and Influences Cell Survival and Proliferation
Cancer Res., May 1, 2007; 67(9): 4287 - 4294.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. A. Deane, M. G. Kharas, J. S. Oak, L. N. Stiles, J. Luo, T. I. Moore, H. Ji, C. Rommel, L. C. Cantley, T. E. Lane, et al.
T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling
Blood, April 1, 2007; 109(7): 2894 - 2902.
[Abstract] [Full Text] [PDF]


Home page
ASH ANNUAL MEETING ABSTRACTSHome page
J. Tamburini, N. Chapuis, V. Bardet, S. Park, F. Verdier, F. Dreyfus, C. Lacombe, and D. Bouscary
Rational for Specific Inhibition of Both PI3K/AKT and mTORC1 Activities in Acute Myelogenous Leukaemia.
Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 1904 - 1904.
[Abstract] [PDF]


Home page
Cancer Res.Home page
Z. Zeng, I. J. Samudio, W. Zhang, Z. Estrov, H. Pelicano, D. Harris, O. Frolova, N. Hail Jr., W. Chen, S. M. Kornblau, et al.
Simultaneous Inhibition of PDK1/AKT and Fms-Like Tyrosine Kinase 3 Signaling by a Small-Molecule KP372-1 Induces Mitochondrial Dysfunction and Apoptosis in Acute Myelogenous Leukemia.
Cancer Res., April 1, 2006; 66(7): 3737 - 3746.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Kang, A. Denley, B. Vanhaesebroeck, and P. K. Vogt
Oncogenic transformation induced by the p110beta, -{gamma}, and -{delta} isoforms of class I phosphoinositide 3-kinase
PNAS, January 31, 2006; 103(5): 1289 - 1294.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020